Literature DB >> 23704554

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Ina Tesseur1, Adrian C Lo, Anouk Roberfroid, Sofie Dietvorst, Bianca Van Broeck, Marianne Borgers, Harrie Gijsen, Diederik Moechars, Marc Mercken, John Kemp, Rudi D'Hooge, Bart De Strooper.   

Abstract

Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) tested bexarotene as a potential β-amyloid-lowering drug for Alzheimer's disease (AD). We were not able to reproduce the described effects in several animal models. Drug formulation appears very critical. Our data call for extreme caution when considering this compound for use in AD patients.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23704554     DOI： 10.1126/science.1233937

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  79 in total

1.  Relaunching an old drug: the potential role of bexarotene in neurodegenerative diseases.

Authors:  Javier Riancho; Maria T Berciano; Jose Berciano; Miguel Lafarga
Journal:  J Neurol       Date:  2016-01-02       Impact factor: 4.849

Review 2.  Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.

Authors:  Miguel Moutinho; Gary E Landreth
Journal:  J Lipid Res       Date:  2017-03-06       Impact factor: 5.922

Review 3.  Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging.

Authors:  Catherine Bowes Rickman; Sina Farsiu; Cynthia A Toth; Mikael Klingeborn
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-13       Impact factor: 4.799

4.  Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer's β-amyloid peptides.

Authors:  Jacques Fantini; Coralie Di Scala; Nouara Yahi; Jean-Denis Troadec; Kevin Sadelli; Henri Chahinian; Nicolas Garmy
Journal:  ACS Chem Neurosci       Date:  2014-01-12       Impact factor: 4.418

5.  CSF Apo-E levels associate with cognitive decline and MRI changes.

Authors:  Jon B Toledo; Xiao Da; Michael W Weiner; David A Wolk; Sharon X Xie; Steven E Arnold; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-01-03       Impact factor: 17.088

6.  Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy.

Authors:  Valerie Bomben; Jerrah Holth; John Reed; Paige Cramer; Gary Landreth; Jeffrey Noebels
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

7.  Preclinical data reproducibility for R&D--the challenge for neuroscience.

Authors:  Thomas Steckler
Journal:  Psychopharmacology (Berl)       Date:  2015-01-14       Impact factor: 4.530

8.  Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease.

Authors:  Xueli Zhang; Yanli Tian; Can Zhang; Xiaoyu Tian; Alana W Ross; Robert D Moir; Hongbin Sun; Rudolph E Tanzi; Anna Moore; Chongzhao Ran
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-21       Impact factor: 11.205

9.  ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.

Authors:  Angela W Corona; Nathan Kodoma; Brad T Casali; Gary E Landreth
Journal:  J Neuroimmune Pharmacol       Date:  2015-07-15       Impact factor: 4.147

10.  PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis.

Authors:  Audrey S Dickey; Dafne N Sanchez; Martin Arreola; Kunal R Sampat; Weiwei Fan; Nicolas Arbez; Sergey Akimov; Michael J Van Kanegan; Kohta Ohnishi; Stephen K Gilmore-Hall; April L Flores; Janice M Nguyen; Nicole Lomas; Cynthia L Hsu; Donald C Lo; Christopher A Ross; Eliezer Masliah; Ronald M Evans; Albert R La Spada
Journal:  Sci Transl Med       Date:  2017-12-06       Impact factor: 17.956
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.